Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
August 13, 2018
ArQule Announces Publication of Preclinical Data for ARQ 531, a Reversible Inhibitor of Both Wild Type and Mutant BTK
ArQule, Inc. (ARQL), today announced the publication of preclinical study data for ARQ 531, the Company’s rationally-designed, reversible inhibitor of both wild type and C481S-mutant ...
August 13, 2018
Acer Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update
NEWTON, Mass., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for ...
August 13, 2018
Achaogen to Present at the Wedbush PacGrow Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address ...
August 13, 2018
STRATA Skin Sciences Reports Second Quarter 2018 Financial Results
HORSHAM, Pa., Aug. 13, 2018 (GLOBE NEWSWIRE) -- (SSKN) STRATA Skin Sciences, Inc. (“STRATA”) a medical technology company in Dermatology and Plastic Surgery dedicated to ...
August 13, 2018
Gemphire Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update
LIVONIA, Mich., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, ...
August 13, 2018
Mustang Bio Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights
NEW YORK, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (MBIO), a Fortress Biotech (FBIO) Company focused on the development of novel immunotherapies ...
August 13, 2018
Basilea reports on first Cresemba® approval in MENA region
Basel, Switzerland, August 13, 2018 - Basilea Pharmaceutica Ltd. (SIX:BSLN) announced today that its partner Hikma Pharmaceuticals LLC, gained regulatory approval for the antifungal Cresemba® ...
August 13, 2018
RedHill Biopharma Receives Allowance for New U.S. Patent Covering RHB-104 for Crohn’s Disease and RHB-204 for NTM Infections
TEL-AVIV, Israel and RALEIGH, N.C., Aug. 13, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty ...
August 13, 2018
Athenex Pharma Solutions, an Athenex, Inc. Company, Launches Compounded Vasopressin Injection in Ready-to-Use Premix IV Bags
BUFFALO, N.Y., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for ...
August 13, 2018
Mustang Bio and St. Jude Children’s Research Hospital Enter into Exclusive Worldwide License Agreement for a Ground-Breaking, Clinical-Stage Lentiviral Gene Therapy with Curative Potential for X-linked Severe Combined Immunodeficiency
NEW YORK and MEMPHIS, Tenn., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (MBIO), a Fortress Biotech (FBIO) Company focused on the development ...
August 13, 2018
Catalyst Biosciences Announces Oral Presentation at the 2018 Hemophilia Drug Development Summit
SOUTH SAN FRANCISCO, Calif., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address ...
August 13, 2018
Checkpoint Therapeutics Announces Clinical Data on EGFR Inhibitor CK-101 Selected for Late-Breaking Oral Presentation at IASLC 19th World Conference on Lung Cancer
NEW YORK, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization ...
August 13, 2018
Eiger BioPharmaceuticals Announces Completion of Enrollment in Phase 2 PREVENT Study of Avexitide (formerly Exendin 9-39) in Patients Suffering from Post-Bariatric Hypoglycemia
PALO ALTO, Calif., Aug. 13, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced completion ...
August 13, 2018
AIT Therapeutics Announces $20 Million Common Stock Purchase Agreement with Institutional Investor, Lincoln Park Capital Fund
GARDEN CITY, N.Y., and REHOVOT, Israel, Aug. 13, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (AITB) (“AIT Therapeutics or the “Company”),  a clinical-stage medical device ...
August 10, 2018
Gemphire Announces Termination of Phase 2a Clinical Trial of Gemcabene in Pediatric NAFLD
LIVONIA, Mich., Aug. 10, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, ...
August 10, 2018
ADMA Biologics Reports Second Quarter 2018 Financial Results
RAMSEY, N.J. and BOCA RATON, Fla., Aug. 10, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”) today announced its financial results ...
August 10, 2018
Prometic announces the publication of PBI-4050's antifibrotic activity in liver diseases in Journal of Pharmacology and Experimental Therapeutics
LAVAL, QC , Aug. 10, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) ("Prometic") today announced the publication of a paper further elucidating the ...
August 10, 2018
Eiger BioPharmaceuticals Reports Second Quarter 2018 Financial Results
PALO ALTO, Calif., Aug. 10, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today ...
August 9, 2018
Sierra Oncology Reports Second Quarter Results
VANCOUVER, Aug. 9, 2018 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) ...
August 9, 2018
InflaRx N.V. Reports Second Quarter 2018 Financial & Operating Results
JENA, Germany, Aug. 09, 2018 (GLOBE NEWSWIRE) -- InflaRx N.V. (IFRX), a biopharmaceutical company developing innovative therapeutics to treat life-threatening inflammatory diseases by targeting the ...
Page 23 of 117